Want to see ARWR full AI Analyst Report?

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

1,706 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARWR Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Arrowhead

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARWR Stock 12 Month Forecast

Average Price Target

$103.96

▲(21.45% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $103.96 with a high forecast of $126.00 and a low forecast of $46.00. The average price target represents a 21.45% change from the last price of $85.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","127":"$127","42.25":"$42.3","70.5":"$70.5","98.75":"$98.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":126,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$126.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.96272727272729,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,42.25,70.5,98.75,127],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.65,87.83076923076923,91.01153846153846,94.1923076923077,97.37307692307692,100.55384615384615,103.73461538461538,106.91538461538462,110.09615384615384,113.27692307692308,116.4576923076923,119.63846153846154,122.81923076923077,{"y":126,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.65,86.13559440559442,87.62118881118882,89.10678321678323,90.59237762237763,92.07797202797204,93.56356643356645,95.04916083916085,96.53475524475526,98.02034965034966,99.50594405594407,100.99153846153848,102.47713286713288,{"y":103.96272727272729,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.65,81.67692307692309,78.70384615384616,75.73076923076924,72.75769230769231,69.78461538461539,66.81153846153846,63.838461538461544,60.86538461538461,57.892307692307696,54.919230769230765,51.94615384615385,48.973076923076924,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.44,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.65,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$126.00

Average Price Target$103.96

Lowest Price Target$46.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$115→$120

Buy

40.19%

Upside

Reiterated

08/07/26

Arrowhead price target raised to $120 from $115 at H.C. WainwrightArrowhead price target raised to $120 from $115 at H.C. Wainwright

Brian Cheng

J.P. Morgan

$95→$100

Buy

16.82%

Upside

Reiterated

08/06/26

J.P. Morgan Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Michael Ulz

Morgan Stanley

$120

Buy

40.19%

Upside

Assigned

08/06/26

Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

Madison Elsaadi

B. Riley Securities

$123

Buy

43.69%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)

James Condulis

Stifel Nicolaus

$98→$104

Buy

21.50%

Upside

Reiterated

08/05/26

Arrowhead price target raised to $104 from $98 at StifelArrowhead price target raised to $104 from $98 at Stifel

Edward Tenthoff

Piper Sandler

$126

Buy

47.20%

Upside

Reiterated

08/05/26

Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Luca Issi

RBC Capital

$100

Buy

16.82%

Upside

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)

Jason Gerberry

Bank of America Securities

$100

Buy

16.82%

Upside

Reiterated

08/04/26

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

Joseph Thome

TD Cowen

$89.59

Buy

4.66%

Upside

Assigned

08/04/26

Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating

Keay Nakae

Chardan Capital

$115

Buy

34.35%

Upside

Reiterated

08/04/26

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

William Pickering

Bernstein

$35→$46

Hold

-46.26%

Downside

Assigned

05/13/26

Arrowhead price target raised to $46 from $35 at BernsteinArrowhead price target raised to $46 from $35 at Bernstein

Mani Foroohar

Leerink Partners

―

Hold

―

Reiterated

03/26/26

Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)

Andrea Newkirk

Goldman Sachs

$50→$85

Hold

-0.70%

Downside

Reiterated

01/07/26

Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$67

Buy

-21.73%

Downside

Reiterated

12/05/25

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies

David Lebowitz

Citi

$27.8→$17

Hold

-80.14%

Downside

Reiterated

09/03/25

Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$115→$120

Buy

40.19%

Upside

Reiterated

08/07/26

Arrowhead price target raised to $120 from $115 at H.C. WainwrightArrowhead price target raised to $120 from $115 at H.C. Wainwright

Brian Cheng

J.P. Morgan

$95→$100

Buy

16.82%

Upside

Reiterated

08/06/26

J.P. Morgan Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Michael Ulz

Morgan Stanley

$120

Buy

40.19%

Upside

Assigned

08/06/26

Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

Madison Elsaadi

B. Riley Securities

$123

Buy

43.69%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)

James Condulis

Stifel Nicolaus

$98→$104

Buy

21.50%

Upside

Reiterated

08/05/26

Arrowhead price target raised to $104 from $98 at StifelArrowhead price target raised to $104 from $98 at Stifel

Edward Tenthoff

Piper Sandler

$126

Buy

47.20%

Upside

Reiterated

08/05/26

Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

Luca Issi

RBC Capital

$100

Buy

16.82%

Upside

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)

Jason Gerberry

Bank of America Securities

$100

Buy

16.82%

Upside

Reiterated

08/04/26

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

Joseph Thome

TD Cowen

$89.59

Buy

4.66%

Upside

Assigned

08/04/26

Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating

Keay Nakae

Chardan Capital

$115

Buy

34.35%

Upside

Reiterated

08/04/26

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

William Pickering

Bernstein

$35→$46

Hold

-46.26%

Downside

Assigned

05/13/26

Arrowhead price target raised to $46 from $35 at BernsteinArrowhead price target raised to $46 from $35 at Bernstein

Mani Foroohar

Leerink Partners

―

Hold

―

Reiterated

03/26/26

Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)

Andrea Newkirk

Goldman Sachs

$50→$85

Hold

-0.70%

Downside

Reiterated

01/07/26

Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$67

Buy

-21.73%

Downside

Reiterated

12/05/25

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies

David Lebowitz

Citi

$27.8→$17

Hold

-80.14%

Downside

Reiterated

09/03/25

Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arrowhead Pharmaceuticals

3 Months

Patrick TrucchioH.C. Wainwright

Success Rate

18/26 ratings generated profit

Average Return

+28.19%

Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +28.19% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

22/26 ratings generated profit

Average Return

+129.73%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +129.73% per trade.

2 Years

Patrick TrucchioH.C. Wainwright

Success Rate

25/26 ratings generated profit

Average Return

+210.59%

Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 96.15% of your transactions generating a profit, with an average return of +210.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARWR Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARWR has received 30 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARWR average Analyst price target in the past 3 months is 103.96.

Each month's total comprises the sum of three months' worth of ratings.

ARWR Financial Forecast

ARWR Earnings Forecast

Next quarter’s earnings estimate for ARWR is -$1.52 with a range of -$3.00 to -$0.35. The previous quarter’s EPS was -$1.36. ARWR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Sales Forecast

Next quarter’s sales forecast for ARWR is $71.76M with a range of $4.50M to $178.00M. The previous quarter’s sales results were $75.25M. ARWR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Stock Forecast FAQ

What is ARWR’s average 12-month price target, according to analysts?

Based on analyst ratings, Arrowhead Pharmaceuticals, Inc.’s 12-month average price target is 103.96.

What is ARWR’s upside potential, based on the analysts’ average price target?

Arrowhead Pharmaceuticals, Inc. has 21.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARWR a Buy, Sell or Hold?

Arrowhead Pharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Arrowhead Pharmaceuticals, Inc.’s price target?

The average price target for Arrowhead Pharmaceuticals, Inc. is 103.96. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $126.00 ,the lowest forecast is $46.00. The average price target represents 21.45% Increase from the current price of $85.6.

What do analysts say about Arrowhead Pharmaceuticals, Inc.?

Arrowhead Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of ARWR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

ARWR Analyst Ratings

ARWR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arrowhead Pharmaceuticals

ARWR Analyst Recommendation Trends

ARWR Financial Forecast

ARWR Earnings Forecast

ARWR Sales Forecast

ARWR Stock Forecast FAQ

Detailed List of Analyst Forecasts